WARF: P100036US02

Simple Test for Diagnosing Antibody-Mediated Rejection in Patients with a Kidney Transplant


Debra Bloom, Hans Sollinger, Arjang Djamali

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing an inexpensive, non-invasive and predictive test for antibody-mediated rejection in renal transplant patients.
OVERVIEWAlmost 90,000 Americans develop end-stage renal disease each year.  Kidney transplantation is the best therapy for these patients and offers them an improved quality of life. 

Although many kidney grafts are successful in the short term, long-term maintenance of the grafts is poor.  A primary cause of transplant failure is cell-mediated rejection (CMR).  Antibody-mediated rejection (AMR), which affects 10 to 15 percent of patients, has emerged as another important cause of graft damage and eventual loss.  Unlike other forms of rejection, AMR frequently is irreversible.  Early diagnosis and monitoring of AMR could allow physicians to make informed decisions about anti-rejection therapies, but no inexpensive, single, straightforward test for conclusively diagnosing AMR is available currently.
THE INVENTIONUW-Madison researchers have identified biomarkers that can be used to detect or predict AMR in kidney transplant patients.  Patients whose urine contains a factor called BAFF, which is known to activate B cells, have or are likely to develop AMR.  Additional biomarkers, including other members of the tumor necrosis factor ligand family as well as chemokines, also are useful for monitoring AMR.
  • Diagnosing AMR in renal transplant patients
  • Distinguishing AMR from CMR
  • Determining efficacy of anti-rejection treatment
  • Predicting likelihood of success for a long-term allograft
  • Monitoring other inflammatory conditions, including rheumatoid arthritis, diabetes mellitus and multiple sclerosis, among others
  • Non-invasive
  • Inexpensive
  • Straightforward
  • Simple
  • Several biological samples, including urine, blood, serum and plasma, can be used.
STAGE OF DEVELOPMENTIn a small sample set of people who received a kidney transplant, BAFF was only found in the urine of patients who had or who would go on to develop AMR.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.